A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors

類似資料

• A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
  著者:: Gordon, Michael S., 等
  出版事項: (2012)
• A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours
  著者:: Eskens, F A L M, 等
  出版事項: (2008)
• A Phase 1 Trial Dose Escalation Study of Tipifarnib on a Week-On, Week-Off Schedule in Relapsed, Refractory or High-Risk Myeloid Leukemia
  著者:: Kirschbaum, Mark, 等
  出版事項: (2011)
• Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors
  著者:: Awada, A. H., 等
  出版事項: (2012)
• Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
  著者:: Schnell, David, 等
  出版事項: (2014)